Holstein SA, Atrash S, Mian H, Dimopoulos MA, Schjesvold F, Popat R, Shah N, Gatt ME, Gocke CB, Frenzel L, Touzeau C, Beksac M, Manier S, Magen H, Travis P, Nadeem O, Suryanarayan K, Li C, Li S, Nelson A, Cherepanov D, Parot X, Vogl DT(2025) A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma Blood(in press) DOI 10.1182/blood.2024027873, PubMed 40279508
Gundesen MT, Schjesvold F, Lund T(2025) Treatment of myeloma bone disease: When, how often, and for how long? J Bone Oncol, 52, 100680 DOI 10.1016/j.jbo.2025.100680, PubMed 40242221
Richter J, Nooka A, RodrÃguez-Otero P, Schjesvold F, Katodritou E, Combe E, Scott M, Cooper L, Sly I, Ballew N, Bitetti J, Boytsov N, Purser M, McNamara S(2025) Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis Am J Hematol(in press) DOI 10.1002/ajh.27661, PubMed 40143674
